- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07342608
Sécurité et performances de la sonde de stimulation cardiaque LINEA optimisée pour l'implantation dans le septum interventriculaire (STARLIGHT)
Sécurité et Performances de la Sonde de Stimulation Cardiaque LINEA Optimisée pour l'Implantation dans le Septum Interventriculaire
The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Antoine Guihard
- Numéro de téléphone: +33 1 46 01 33 20
- E-mail: antoine.guihard@cf.microport.com
Lieux d'étude
-
-
-
Ghent, Belgique
- Recrutement
- Ghent University Hospital
-
Contact:
- Jan De Pooter
- E-mail: jadpoote.depooter@ugent.be
-
-
-
-
-
Girona, Espagne
- Recrutement
- Hospital Universitari de Girona Doctor Josep Trueta
-
Contact:
- María Emilce Trucco
- E-mail: metrucco.girona.ics@gencat.cat
-
Granada, Espagne
- Recrutement
- Hospital Universitario Virgen de las Nieves
-
Contact:
- Manuel Molina
- E-mail: manuel.molina.lerma@gmail.com
-
Valencia, Espagne
- Recrutement
- Hospital Universitari i Politècnic La Fe
-
Contact:
- Óscar Cano
- E-mail: oscape13@hotmail.com
-
-
-
-
-
Annecy, France
- Recrutement
- Centre Hospitalier Annecy Genevois
-
Contact:
- Pierre Frey
- E-mail: pfrey@ch-annecygenevois.fr
-
Clermont-Ferrand, France
- Recrutement
- CHU Clermont-Ferrand
-
Contact:
- Pierre-Antoine Catalan
- E-mail: pacatalan@chu-clermontferrand.fr
-
Grenoble, France
- Recrutement
- CHU Grenoble
-
Contact:
- Adrien Carabelli
- E-mail: acarabelli@chu-grenoble.fr
-
Montpellier, France
- Recrutement
- Clinique du Millénaire
-
Contact:
- Nicolas Clémenty
- E-mail: nicolas.clementy@gmail.com
-
Rouen, France
- Recrutement
- CHU Rouen Hôpital Charles Nicolle
-
Contact:
- Raphaël Al Hamoud
- E-mail: raphael.al-hamoud@chu-rouen.fr
-
Tours, France
- Recrutement
- Hôpital Trousseau
-
Contact:
- Arnaud Bisson
- E-mail: a.bisson@chu-tours.fr
-
-
-
-
-
Novara, Italie
- Recrutement
- Ospedale Maggiore della Carità - AO Univ.
-
Contact:
- Gabriele Dell'Era
- E-mail: gabriele.dellera@maggioreosp.novara.it
-
Pisa, Italie
- Recrutement
- Ospedale San Cataldo CNR - Fond. Toscana G. Monasterio
-
Contact:
- Gianluca Mirizzi
- E-mail: gmirizzi@ftgm.it
-
-
-
-
-
Coimbra, Le Portugal
- Recrutement
- ULS de Coimbra
-
Contact:
- João Ferreira
- E-mail: joaoaferreira29@gmail.com
-
Lisbon, Le Portugal
- Recrutement
- ULS Santa Maria
-
Contact:
- Nelson Cunha
- E-mail: nelsoncunha@campus.ul.pt
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion criteria (phase I and II):
- Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
- Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM
- Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area
- Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated
Exclusion criteria (phase I and II):
- Patient planned for a device upgrade, or a device or a lead replacement
- Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy
- Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%
- Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
- Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
- Patient with a life expectancy of less than 2 years
- Minor age patient (i.e. under 18 years of age)
- Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
- Non-menopausal women
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Sonde de stimulation cardiaque LINEA
|
Use of LINEA cardiac pacing lead and delivery catheter for implantation of pacemaker |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
LINEA lead complication free rate at 3 months
Délai: 3 months after implantation
|
Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
3 months after implantation
|
|
LINEA lead pacing threshold amplitude at 3 months
Délai: 3 months after implantation
|
Mean ventricular pacing threshold amplitude |
3 months after implantation
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Success rate of LINEA lead minimum sensed amplitude
Délai: 3 months after implantation
|
Proportion of patients with minimum sensed amplitude ≥ 5 mV |
3 months after implantation
|
|
General performances of LINEA lead
Délai: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
Pacing threshold amplitude, impedance and minimum sensed amplitude obtained with the LINEA lead at each patient's visit. LBB pacing threshold amplitude obtained with the LINEA lead during implantation, as well as the chronaxie measurement |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the LINEA lead
Délai: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
LINEA lead complication free rate over time, calculated based on number of Adverse Events and Device Deficiencies related to the lead |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the FLEXIGO delivery catheter and the FLEXIGO slitter
Délai: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
FLEXIGO catheter complication free rate, calculated based on number of Adverse Events and Device Deficiencies related to the catheter or the slitter |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
LINEA lead implantation success rates
Délai: Implantation
|
Proportion of LINEA leads implanted in the interventricular septum and meeting or not LBBAP criteria |
Implantation
|
|
Lead and delivery catheter implantation time
Délai: Implantation
|
Total procedural time and total fluoroscopic time of each implantation |
Implantation
|
|
LINEA lead and FLEXIGO delivery catheter and slitter implantation usability
Délai: Implantation
|
Handling scores based on a specific questionnaire (scale Very poor/Poor/Acceptable/Good/Very good) |
Implantation
|
|
Right Ventricular Autothreshold performances
Délai: 3 months after implantation
|
- Accuracy - Comparison between the manual ventricular pacing threshold performed by a physician and the in-clinic ventricular pacing threshold provided by the RVAT function at the same pulse width and during the same on-site patient's visit |
3 months after implantation
|
|
Evolution of LBBAP capture over time
Délai: 18 months after implantation
|
- LBBAP capture evolution with analyses of ECGs (i.e. V6 R-wave peak time and V6-V1 interpeak interval) and LBBAP criteria collected |
18 months after implantation
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Early outcome - Absence of Unanticipated Serious Adverse Device Effect (USADE) related to LINEA lead
Délai: 1 month after implantation
|
Proportion of patients free from USADE. Any event caused by use of the LINEA lead or any accessory packaged with the lead, will be considered as an ADE related to the LINEA lead. The endpoint evaluation will be based on an independent safety events adjudication from a Clinical Events Committee (CEC), based on investigational site reporting |
1 month after implantation
|
|
Early outcome - LINEA lead pacing threshold amplitude at 1 month
Délai: 1 month after implantation
|
Mean ventricular pacing threshold amplitude |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Délai: 1 month after implantation
|
- Implantation success rate - Proportion of LINEA lead successfully implanted at the interventricular septum and fulfilling or not LBBAP success criteria according to the operator's decision |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Délai: 1 month after implantation
|
- Short term electrical performances variation - Pacing threshold variation between implantation and 1 month, and electrical performances of the LINEA lead (pacing threshold, impedance and minimum sensed amplitude) |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Délai: 1 month after implantation
|
- Complication free rate - Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
1 month after implantation
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- LLAI01 - STARLIGHT
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .